Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Liabilities and Shareholders Equity (2017 - 2025)

Puma Biotechnology's Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $216.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 1.39% year-over-year to $216.3 million; the TTM value through Dec 2025 reached $810.3 million, down 5.03%, while the annual FY2025 figure was $216.3 million, 1.39% up from the prior year.
  • Liabilities and Shareholders Equity reached $216.3 million in Q4 2025 per PBYI's latest filing, up from $202.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $260.0 million in Q2 2021 to a low of $193.7 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $214.1 million, with a median of $209.2 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: rose 14.69% in 2021, then dropped 25.52% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $226.6 million in 2021, then decreased by 2.0% to $222.1 million in 2022, then grew by 3.81% to $230.5 million in 2023, then decreased by 7.46% to $213.3 million in 2024, then rose by 1.39% to $216.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Liabilities and Shareholders Equity are $216.3 million (Q4 2025), $202.9 million (Q3 2025), and $194.9 million (Q2 2025).